echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Long-term follow-up of boron neutron capture therapy for recurrent malignant meningioma

    Long-term follow-up of boron neutron capture therapy for recurrent malignant meningioma

    • Last Update: 2023-02-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com







    Satoshi Takai et al.
    of the Department of Neurosurgery, Osaka Medical University, Japan, retrospectively analyzed 44 patients
    with relapsed and refractory meningiomas treated with BNCT and long-term follow-up from 2005 to 2019.

    The results were published in the January 2022 issue of the journal
    Neuro-Oncology.



    - Excerpted from the article chapter


    Ref: Takai S, et al.
    Neuro Oncol.
    2022 Jan 5; 24(1):90-98.
    doi: 10.
    1093/neuonc/noab108.


    Research background




    High-grade meningioma (HGM), especially relapsed and refractory meningioma, is poorly treated, and there is currently no standard treatment regimen
    .

    Boron Neutron Therapy (BNCT) is a new type of particle radiotherapy that can theoretically selectively kill tumor cells and is a biological cell-targeted radiotherapy
    .

    Satoshi Takai et al.
    of the Department of Neurosurgery, Osaka Medical University, Japan, retrospectively analyzed 44 patients
    with relapsed and refractory meningiomas treated with BNCT and long-term follow-up from 2005 to 2019.

    The results were published in the January 2022 issue of the journal
    Neuro-Oncology.


    Study results



    The researchers evaluated
    tumor size, overall survival (OS) and progression-free survival (PFS) after BNCT, and the reasons for treatment failure in 44 patients.

    The results showed that the median OS after BNCT was 29.
    6 months (95% CI: 16.
    1-40.
    4)
    in all patients.

    The median follow-up after BNCT was 26 months (6.
    4-103).


    Among them, the median OS after BNCT for WHO grade 2 (20 cases) and WHO grade 3 (24 cases) meningioma was 44.
    4 months and 21.
    55 months, respectively (P=0.
    0009).


    After 36 high-grade meningiomas BNCT treatment, 35 cases showed tumor shrinkage on imaging after 3 months; PFS after BNCT was 13.
    7 months (95% CI: 8.
    3 to 28.
    6).


    The median PFS after BNCT was 24.
    3 months and 9.
    4 months (6.
    3-14.
    4) (P=0.
    0024) in WHO grade 2 and WHO grade 3 meningiomas, respectively, and local recurrence
    was observed in only 22.
    2% of patients.


    Conclusion of the study



    In summary, most patients with relapsed and refractory meningiomas have relatively large tumors and a high proportion of WHO grade 3, which seems to have a poor
    prognosis.

    However, treatment with reactor BNCT yields good survival rates
    .


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.